If you or a family member have cutaneous lupus erythematosus (CLE)
and/or systemic lupus erythematosus (SLE), you may want to consider the
LILAC clinical research study.
What is the purpose of the LILAC study?
The
purpose of the LILAC study is to learn if an investigational medication
may effectively reduce lupus skin activity in patients with CLE and/or
SLE.
What is the investigational medication?
The
investigational medication, BIIB059, is a monoclonal antibody
administered as a subcutaneous injection. Antibodies are designed to
recognize and attach to specific molecules in your body. BIIB059
attaches to the surface of a specific type of cell that is part of the
immune system. When BIIB059 attaches to the immune system cells, it
limits the production of certain protein, called IFNα, which may be
associated with CLE and SLE symptoms. Who can participate in the LILAC
study?
You may be able to participate in this study if you:
• Are 18 to 75 years old
• Have been diagnosed with CLE and/or SLE
• Have active lupus skin disease
How long is the study?
If you are eligible for the study, your participation may last 28 to 40 weeks and include up to 13 visits to the study site.
Click Here to view more details
No comments:
Post a Comment